Castle Biosciences' Says Study Validates DecisionDx-Melanoma's Performance in Providing Personalized Prognosis of Melanoma Recurrence
Castle Biosciences' Says Study Validates DecisionDx-Melanoma's Performance in Providing Personalized Prognosis of Melanoma Recurrence
城堡生物科学公司表示，研究证实Dx-黑色素瘤在提供黑色素瘤复发的个性化预后方面的表现
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册